Search results
2 High-Yield Dividend Stocks to Buy Right Now | The Motley Fool
The Motley Fool· 4 days agoDividend stocks are sensitive to interest rates. When rates fall, studies show that money managers...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks via Yahoo Finance· 2 days agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 1 day agoThe biotech group ranks No. 40 out of 197 industry groups that IBD tracks. Meanwhile, the pharma...
Is Moderna Stock A Buy After Its Second-Ever Product Snags FDA Approval?
Investor's Business Daily· 2 days agoSo, MRNA stock ranks narrowly inside the top half of all stocks, regardless the industry group, on...
Paxlovid Fails to Quell Long Covid Symptoms in Stanford Study
Bloomberg· 1 day agoA 15-day course of Pfizer Inc.’s antiviral Paxlovid didn’t provide significant relief for long Covid...
AbbVie's tight grip on Humira market raises concerns about biosimilars
Colorado Springs Gazette· 2 days agoHumira, which lists for almost $7,000 a month, is the first top-selling drug to compete with a slew of biosimilars, which are close but not exact copies of branded biologic ...
Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU
Zacks via Yahoo Finance· 3 days agoHalozyme (HALO) is set to benefit from the new patent grant in the EU, ensuring the protection of...
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Investor's Business Daily· 1 day agoShares continued to climb, hitting a recent intraday high at 23.86 on June 6. Shares now have a top...
Germany’s Merck Bets on AI Drug-Design Partnerships, Rules Out Acquisitions – Interview
The Wall Street Journal· 2 days agoMerck—known as EMD Group in the U.S.— is betting on artificial-intelligence partnerships to develop...
GSK Stock Dips on Delaware Court Ruling for Zantac Litigation
Zacks via Yahoo Finance· 5 days agoGSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling...